Overview

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
MDS/AML with MRD and impending relapse after allogeneic stem cell transplantation and/or conventional chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
University of Leipzig
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
Azacitidine
Pevonedistat